[go: up one dir, main page]

SE9801148D0 - New receptors - Google Patents

New receptors

Info

Publication number
SE9801148D0
SE9801148D0 SE9801148A SE9801148A SE9801148D0 SE 9801148 D0 SE9801148 D0 SE 9801148D0 SE 9801148 A SE9801148 A SE 9801148A SE 9801148 A SE9801148 A SE 9801148A SE 9801148 D0 SE9801148 D0 SE 9801148D0
Authority
SE
Sweden
Prior art keywords
vdrr
polypeptides
methods
polypeptide
novel
Prior art date
Application number
SE9801148A
Other languages
Swedish (sv)
Inventor
Anders Berkenstam
Mats Dahlberg
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9703745A external-priority patent/SE9703745D0/en
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Priority to SE9801148A priority Critical patent/SE9801148D0/en
Publication of SE9801148D0 publication Critical patent/SE9801148D0/en
Priority to JP2000515925A priority patent/JP2001519441A/en
Priority to CNB988112264A priority patent/CN1134452C/en
Priority to KR1020007004011A priority patent/KR20010031120A/en
Priority to EP98941985A priority patent/EP1023323A1/en
Priority to CA002306453A priority patent/CA2306453A1/en
Priority to AU90131/98A priority patent/AU732079B2/en
Priority to US09/143,828 priority patent/US7118885B2/en
Priority to PCT/SE1998/001548 priority patent/WO1999019354A1/en
Priority to NZ504025A priority patent/NZ504025A/en
Priority to US11/369,263 priority patent/US20060228778A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to novel vitamin D receptor related (VDRR) polypeptides, and formulations containing the same. Nucleic acid sequences encoding the VDRR polypeptides, expression vectors containing such sequences and host cells transformed with such expression vectors are also disclosed, as are methods for the expression of the novel VDRR polypeptides of the invention. The invention further relates to VDRR polypeptides for use as medicaments, and use of substances affecting VDRR signal transduction for the manufacture of medicaments for treating metabolic, proliferative or inflammatory conditions. The present invention also relates to methods for identifying clones encoding a VDRR polypeptide, methods for identifying ligands to a VDRR and methods for identifying substances for treatment of conditions affected by a VDRR polypeptide. More specifically, the novel VDRR polypeptide can be the polypeptide designated VDRR gamma , which may be regulated by any small chemical molecule similar in structure to known ligands for nuclear receptors.
SE9801148A 1997-10-14 1998-03-31 New receptors SE9801148D0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SE9801148A SE9801148D0 (en) 1997-10-14 1998-03-31 New receptors
NZ504025A NZ504025A (en) 1997-10-14 1998-08-31 Vitamin D receptor related polypeptides (VDRR) and its use in treating inflammatory disease
PCT/SE1998/001548 WO1999019354A1 (en) 1997-10-14 1998-08-31 Novel vitamin d receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof
KR1020007004011A KR20010031120A (en) 1997-10-14 1998-08-31 Novel vitamin d receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof
CNB988112264A CN1134452C (en) 1997-10-14 1998-08-31 Vitamin D receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof
JP2000515925A JP2001519441A (en) 1997-10-14 1998-08-31 Novel vitamin D receptor-related polypeptides, nucleic acid sequences encoding such polypeptides and uses thereof
EP98941985A EP1023323A1 (en) 1997-10-14 1998-08-31 Novel vitamin d receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof
CA002306453A CA2306453A1 (en) 1997-10-14 1998-08-31 Novel vitamin d receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof
AU90131/98A AU732079B2 (en) 1997-10-14 1998-08-31 Novel vitamin D receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof
US09/143,828 US7118885B2 (en) 1997-10-14 1998-08-31 Nucleic acid encoding vitamin D receptor related polypeptide
US11/369,263 US20060228778A1 (en) 1997-10-14 2006-03-06 Novel vitamin D receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703745A SE9703745D0 (en) 1997-10-14 1997-10-14 New receptors
SE9801148A SE9801148D0 (en) 1997-10-14 1998-03-31 New receptors

Publications (1)

Publication Number Publication Date
SE9801148D0 true SE9801148D0 (en) 1998-03-31

Family

ID=26663102

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9801148A SE9801148D0 (en) 1997-10-14 1998-03-31 New receptors

Country Status (9)

Country Link
EP (1) EP1023323A1 (en)
JP (1) JP2001519441A (en)
KR (1) KR20010031120A (en)
CN (1) CN1134452C (en)
AU (1) AU732079B2 (en)
CA (1) CA2306453A1 (en)
NZ (1) NZ504025A (en)
SE (1) SE9801148D0 (en)
WO (1) WO1999019354A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1044216A4 (en) * 1997-12-12 2001-10-31 Merck & Co Inc DNA MOLECULES ENCODING HUMAN NUCLEAR RECEPTOR PROTEINS, nNR7 AND nNR7-1
US6756491B2 (en) * 1998-01-09 2004-06-29 The Salk Institute For Biological Studies Steroid-activated nuclear receptors and uses therefor
US6911537B2 (en) * 1998-01-09 2005-06-28 The Salk Institute For Biological Studies Xenobiotic compound modulated expression systems and uses therefor
US6984773B1 (en) 1998-01-09 2006-01-10 The Salk Institute For Biological Studies Transgenic mice expressing a human SXR receptor polypeptide
AU2003200641B2 (en) * 1998-01-09 2008-04-03 The Salk Institute For Biological Studies Novel Steroid-activated Nuclear Receptors and Uses therefor
US7238491B1 (en) 1998-03-27 2007-07-03 Smithkline Beecham Corporation Pregnane X receptor method
JP2002535241A (en) * 1998-03-27 2002-10-22 グラクソ グループ リミテッド Orphan nuclear receptor
FR2801311B1 (en) * 1999-11-22 2005-08-26 Centre Nat Rech Scient POLYPEPTIDES DERIVED FROM THE NUCLEAR RECEPTOR OF VITAMIN D, AND USES THEREOF IN PARTICULAR IN THE SCREENING OF ANALOGUES OF VITAMIN D
AU2006200258B2 (en) * 1999-12-09 2009-04-09 The Salk Institute For Biological Studies Novel steroid-activated nuclear receptors and uses therefor
US6514941B1 (en) 1999-12-10 2003-02-04 Campina Melkunie B.V. Method of preparing a casein hydrolysate enriched in anti-hypertensive peptides
US20040053866A1 (en) * 2002-08-21 2004-03-18 The Regents Of The University Of California Tumor suppressor genes and their uses
SE0400489D0 (en) * 2004-02-27 2004-02-27 Biovitrum Ab Therapeutic proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989009223A1 (en) * 1988-03-30 1989-10-05 Arch Development Corporation Dna binding proteins including androgen receptor
EP0609240B1 (en) * 1991-09-17 2002-04-03 The Salk Institute For Biological Studies Receptors of the thyroid/steroid hormone receptor superfamily
US5756448A (en) * 1992-02-26 1998-05-26 The General Hospital Corporation Constitute activator of retinoid (CAR) receptor polypeptides
WO1996022390A1 (en) * 1995-01-17 1996-07-25 The Salk Institute For Biological Studies Methods, polypeptides, nucleotide sequence of xor-6, a vitamin d-like receptor from xenopus
AU5426596A (en) * 1995-05-16 1996-11-29 Salk Institute For Biological Studies, The Modulators for new members of the steroid/thyroid superfamily of receptors

Also Published As

Publication number Publication date
WO1999019354A9 (en) 1999-12-02
KR20010031120A (en) 2001-04-16
NZ504025A (en) 2003-04-29
AU9013198A (en) 1999-05-03
CN1279689A (en) 2001-01-10
JP2001519441A (en) 2001-10-23
EP1023323A1 (en) 2000-08-02
AU732079B2 (en) 2001-04-12
CN1134452C (en) 2004-01-14
WO1999019354A1 (en) 1999-04-22
CA2306453A1 (en) 1999-04-22

Similar Documents

Publication Publication Date Title
LaRochelle et al. PDGF-D, a new protease-activated growth factor
DE69232537D1 (en) RECEPTORS OF THE STEROID / THYROID SUPERFAMILY OF RECEPTORS
Wang et al. Cloning and expressional characterization of a novel galanin receptor: identification of different pharmacophores within galanin for the three galanin receptor subtypes
Todorov et al. Characterization of a cancer cachectic factor
Rizos et al. Two arginine rich domains in the p14ARF tumour suppressor mediate nucleolar localization
Kurosaki et al. Functional properties of nicotinic acetylcholine receptor subunits expressed in various combinations
SE9801148D0 (en) New receptors
Rudnicka-Nawrot et al. Changes in biological activity and folding of guanylate cyclase-activating protein 1 as a function of calcium
Shimohigashi et al. Sensitivity of opioid receptor-like receptor ORL1 for chemical modification on nociceptin, a naturally occurring nociceptive peptide
DE69230888D1 (en) SOMATOSTATIN RECEPTORS
DK1005540T3 (en) IKK-beta proteins, nucleic acids and methods
DE69836956D1 (en) RECEPTOR 5 CONTAINING A DOMAIN RESPONSIBLE FOR CELL DEATH
DE69839340D1 (en) Mutants of the VASCULAR, ENDOTHELCELL SPECIFIC GROWTH FACTOR C (VEGF-C) AND THEIR USES
HUP0105337A2 (en) Polypeptides involved in immune response
ATE106940T1 (en) NUCLEIC ACID ENCODING THE T-CELL ANTIGEN RECEPTOR POLYPEPTIDE.
El Tayar et al. The lipophilicity of deuterium atoms. A comparison of shake-flask and HPLC methods
EP0628054A4 (en) CAR RECEPTORS, RELATED MOLECULES AND METHODS OF OBTAINING SAME.
Tolan et al. Radioiodination of microgram quantities of ribosomal proteins from polyacrylamide gels
MXPA02008239A (en) Human schizophrenia gene.
Alzani et al. Mechanism of suramin-induced deoligomerization of tumor necrosis factor. alpha.
Okamoto et al. Insulin-like growth factor-II/mannose 6-phosphate receptor is incapable of activating GTP-binding proteins in response to mannose 6-phosphate, but capable in response to insulin-like growth factor-II
DE69504808D1 (en) CORTICOTROPIN RELEASING RECEPTORS OF FACTOR 2
ATE351905T1 (en) MITOGENE REGULATORS
EP0992584A3 (en) Purified mammalian FLT3 ligands and agonists and antagonists thereof
Van Baelen et al. The heterogeneity of human Gc-globulin.